Literature DB >> 31409525

Prognostic significance of neutrophil-lymphocyte ratio in resectable pancreatic neuroendocrine tumors with special reference to tumor-associated macrophages.

Norifumi Harimoto1, Kouki Hoshino2, Ryo Muranushi2, Kei Hagiwara2, Takahiro Yamanaka2, Norihiro Ishii2, Mariko Tsukagoshi3, Takamichi Igarashi2, Hiroshi Tanaka2, Akira Watanabe2, Norio Kubo2, Kenichirou Araki2, Yasuo Hosouchi4, Hideki Suzuki5, Kazuhisa Arakawa6, Keitarou Hirai7, Takaharu Fukazawa8, Hayato Ikota9, Ken Shirabe2.   

Abstract

BACKGROUND: Recent studies have shown that the systemic inflammatory response induced by cancer leads to cancer progression. Neutrophil-to-lymphocyte ratio (NLR) is the most reliable marker to detect systemic inflammation. In this study, we investigated the significance of NLR in patients with well-differentiated pancreatic neuroendocrine tumors (PanNETs) according to the World Health Organization 2017 classification.
METHODS: We retrospectively collected data for patients with PanNET who underwent pancreatic resection with curative intent between January 2008 and December 2017 at six institutions. Clinicopathological factors, recurrence, and immunohistochemical staining of tumor-associated macrophages (TAMs) were analyzed in a total of 55 patients in this study.
RESULTS: High NLR (>3.41) in patients was significantly associated with higher white blood cell count, higher Ki-67 index, higher mitotic count, higher grade, higher incidence of lymph node metastasis, higher incidence of lymphatic and neural invasion, massive blood loss, and a large number of CD163-expressing TAMs. Recurrence-free survival of patients with high NLR was significantly poorer than that of patients with low NLR. Multivariate analysis identified high NLR, NET Grade 2 (G2) or Grade 3 (G3), and synchronous hepatic resection as independent risk factors for recurrence after curative resection.
CONCLUSIONS: NLR is a promising predictor of recurrence after pancreatectomy that needs to be further investigated and that accumulation of TAMs in the tumor could be one of the causes of NLR elevation.
Copyright © 2019 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Neutrophil-to-lymphocyte ratio; Tumor-associated macrophage; pancreatic neuroendocrine tumor

Mesh:

Year:  2019        PMID: 31409525     DOI: 10.1016/j.pan.2019.08.003

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  11 in total

Review 1.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

2.  Evaluation of the Significance of Lymphatic, Microvascular and Perineural Invasion in Patients With Pancreatic Neuroendocrine Neoplasms.

Authors:  Wataru Izumo; Ryota Higuchi; Toru Furukawa; Takehisa Yazawa; Shuichiro Uemura; Yutaro Matsunaga; Masahiro Shiihara; Yukiko Takayama; Junko Tahara; Kyoko Shimizu; Katsutoshi Tokushige; Masakazu Yamamoto
Journal:  Cancer Diagn Progn       Date:  2022-03-03

Review 3.  The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms.

Authors:  Shuaishuai Xu; Chanqi Ye; Ruyin Chen; Qiong Li; Jian Ruan
Journal:  Cancers (Basel)       Date:  2022-06-13       Impact factor: 6.575

4.  Increased neutrophil-lymphocyte ratio predicts recurrence in patients with well-differentiated pancreatic neuroendocrine neoplasm based on the 2017 World Health Organization classification.

Authors:  Takayuki Miura; Hideo Ohtsuka; Takeshi Aoki; Shuichi Aoki; Tatsuo Hata; Tatsuyuki Takadate; Shimpei Maeda; Kyohei Ariake; Kei Kawaguchi; Kunihiro Masuda; Masaharu Ishida; Masamichi Mizuma; Kei Nakagawa; Takanori Morikawa; Fumiyoshi Fujishima; Takashi Kamei; Hironobu Sasano; Michiaki Unno
Journal:  BMC Surg       Date:  2021-03-31       Impact factor: 2.102

5.  Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Soong June Bae; Yoon Jin Cha; Changik Yoon; Dooreh Kim; Janghee Lee; Soeun Park; Chihwan Cha; Jee Ye Kim; Sung Gwe Ahn; Hyung Seok Park; Seho Park; Seung Il Kim; Joon Jeong
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379

Review 6.  Serum Inflammation-based Scores in Endocrine Tumors.

Authors:  Pedro Marques; Friso de Vries; Olaf M Dekkers; Márta Korbonits; Nienke R Biermasz; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 5.958

7.  Inflammatory markers and long term hematotoxicity of holmium-166-radioembolization in liver-dominant metastatic neuroendocrine tumors after initial peptide receptor radionuclide therapy.

Authors:  Sander C Ebbers; Tessa Brabander; Margot E T Tesselaar; Johannes Hofland; Manon N G J A Braat; Frank J Wessels; Maarten W Barentsz; Marnix G E H Lam; Arthur J A T Braat
Journal:  EJNMMI Res       Date:  2022-02-02       Impact factor: 3.138

Review 8.  Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?

Authors:  Elisa Giannetta; Anna La Salvia; Laura Rizza; Giovanna Muscogiuri; Severo Campione; Carlotta Pozza; Annamaria Anita LIvia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-22       Impact factor: 5.555

9.  Development of a Nomogram Based on Preoperative Bi-Parametric MRI and Blood Indices for the Differentiation Between Cystic-Solid Pituitary Adenoma and Craniopharyngioma.

Authors:  Zhen Zhao; Dongdong Xiao; Chuansheng Nie; Hao Zhang; Xiaobing Jiang; Ali Rajab Jecha; Pengfei Yan; Hongyang Zhao
Journal:  Front Oncol       Date:  2021-07-09       Impact factor: 6.244

10.  Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.

Authors:  Chirayu Mohindroo; Merve Hasanov; Jane E Rogers; Wenli Dong; Laura R Prakash; Seyda Baydogan; Jonathan D Mizrahi; Michael J Overman; Gauri R Varadhachary; Robert A Wolff; Milind M Javle; David R Fogelman; Michael T Lotze; Michael P Kim; Matthew H G Katz; Shubham Pant; Ching-Wei D Tzeng; Florencia McAllister
Journal:  Cancer Med       Date:  2021-07-11       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.